Endpoint Health is a Precision-FirstTM therapeutics company dedicated to addressing unmet needs in immune-mediated acute and chronic diseases. We combine therapeutics, therapy-guiding tests, and AI to develop precision therapies for patients with immune-mediated conditions, such as acute respiratory distress syndrome (ARDS), sepsis, rheumatic and gastroenterologic diseases. Our vision is a world in which all patients get the best treatment possible for their unique biology and disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/02/22 | $52,000,000 | Venture Debt & Equity |
Alix Ventures AME Cloud Ventures Boom Capital Global Health Investment Fund HCX Ventures Humboldt Fund Mayfield The Venture Collective Wireframe Ventures Yaya Capital | undisclosed |
